# A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.

> **NCT05977322** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Gastroesophageal Adenocarcinoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** 68Ga-FF58
- **DRUG:** 177Lu-FF58

## Key facts

- **NCT ID:** NCT05977322
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-06
- **Primary completion:** 2024-12-13
- **Final completion:** 2024-12-13
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The decision was not based on any safety concerns
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05977322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05977322, "A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05977322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*